Opioid agonist therapy.
作者信息
Broad Kathleen, Colon-Rivera Hector Ahmed, Haque Lamia
机构信息
New Haven, CT.
出版信息
Can Fam Physician. 2017 Jul;63(7):509-510.
Abstract
摘要
相似文献
1
Opioid agonist therapy.阿片类激动剂疗法
Can Fam Physician. 2017 Jul;63(7):509-510.
2
Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic.新冠大流行期间阿片类激动剂治疗对阿片类使用障碍患者非致命性药物过量影响的真实世界证据。
J Addict Med. 2023;17(6):e374-e381. doi: 10.1097/ADM.0000000000001213. Epub 2023 Aug 11.
3
Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status.阿片类药物依赖的限时丁丙诺啡替代疗法：与治疗方案完成情况及当前激动剂治疗状态相关的2年随访结果
Drug Alcohol Rev. 2007 Mar;26(2):135-41. doi: 10.1080/09595230601146603.
4
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.阿片类药物成瘾者的阿片类激动剂治疗。
Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3.
5
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.与阿片类物质使用障碍的阿片类激动剂治疗相关的政策：2004年至2013年各州政策的演变
Subst Abus. 2016;37(1):63-9. doi: 10.1080/08897077.2015.1080208. Epub 2015 Nov 13.
6
Qualitative Analysis of Patient Perspectives of Buprenorphine After Transitioning From Long-Term, Full-Agonist Opioid Therapy Among Veterans With Chronic Pain.从长期、完全激动剂阿片类药物治疗过渡到丁丙诺啡的慢性疼痛退伍军人对丁丙诺啡患者观点的定性分析。
J Pain. 2024 Jan;25(1):132-141. doi: 10.1016/j.jpain.2023.07.027. Epub 2023 Aug 6.
7
Opioid agonist treatment for pharmaceutical opioid dependent people.用于药物性阿片类物质依赖者的阿片类激动剂治疗
Cochrane Database Syst Rev. 2016 May 9(5):CD011117. doi: 10.1002/14651858.CD011117.pub2.
8
Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes.在因急性疼痛管理而接受大剂量完全激动剂阿片类药物治疗的住院患者中，快速丁丙诺啡微量滴定治疗阿片类药物使用障碍：滴定、实施障碍以及克服策略。
Subst Abus. 2021;42(4):506-511. doi: 10.1080/08897077.2021.1915914. Epub 2021 May 4.
9
Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine.评估长期接受全μ阿片类激动剂治疗的患者换用口腔含服丁丙诺啡的耐受性
Pain Med. 2016 May;17(5):899-907. doi: 10.1093/pm/pnv110. Epub 2016 Feb 25.
10
Barriers to accessing opioid agonist therapy in pregnancy.孕期获取阿片类激动剂治疗的障碍。
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100225. doi: 10.1016/j.ajogmf.2020.100225. Epub 2020 Sep 15.
引用本文的文献
1
At-a-glance - The local response to the Canadian opioid epidemic in the Kingston, Frontenac, and Lennox and Addington communities.一目了然 - 金斯顿、弗伦特纳克、莱诺克斯和阿丁顿社区对加拿大阿片类药物流行的本地反应。
Health Promot Chronic Dis Prev Can. 2019 Dec;39(12):333-336. doi: 10.24095/hpcdp.39.12.03.
本文引用的文献
1
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.阿片类药物替代治疗期间及之后的死亡风险：队列研究的系统评价和荟萃分析
BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550.
2
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?阿片类物质使用障碍的初级保健管理：禁欲、美沙酮还是丁丙诺啡-纳洛酮？
Can Fam Physician. 2017 Mar;63(3):200-205.
3
Treatment of Opioid-Use Disorders.阿片类物质使用障碍的治疗
N Engl J Med. 2016 Jul 28;375(4):357-68. doi: 10.1056/NEJMra1604339.
4
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.患者对丁丙诺啡/纳洛酮的看法：激动剂替代疗法起始治疗期间留存情况的定性研究（START研究）
J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743.
5
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.在一项多中心试验中，随机接受丁丙诺啡/纳洛酮治疗的患者与接受美沙酮治疗的患者相比，治疗保留率情况。
Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.
6
Drug Addiction Stigma in the Context of Methadone Maintenance Therapy: An Investigation into Understudied Sources of Stigma.美沙酮维持治疗背景下的药物成瘾污名：对未充分研究的污名来源的调查
Int J Ment Health Addict. 2013 Feb 1;11(1):110-122. doi: 10.1007/s11469-012-9402-5.
7
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).丁丙诺啡/纳洛酮和美沙酮维持治疗阿片类镇痛药、海洛因和联合使用者的治疗结局：从使用阿片类激动剂替代疗法（START）开始治疗的结果。
J Stud Alcohol Drugs. 2013 Jul;74(4):605-13. doi: 10.15288/jsad.2013.74.605.
8
Predictors of outcome after short-term stabilization with buprenorphine.短期丁丙诺啡稳定治疗后的结局预测因素。
J Subst Abuse Treat. 2013 Mar;44(3):336-42. doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.
9
Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.比较初次进入美沙酮和丁丙诺啡治疗后患者的治疗保留率和死亡率。
Addiction. 2009 Jul;104(7):1193-200. doi: 10.1111/j.1360-0443.2009.02627.x.
10
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.在初级保健中使用丁丙诺啡/纳洛酮进行长期治疗：2至5年的结果。
Am J Addict. 2008 Mar-Apr;17(2):116-20. doi: 10.1080/10550490701860971.
Zotero 插件